Despite high demand for Evusheld — AstraZeneca’s antibody cocktail meant to prevent COVID-19 in vulnerable patients — physicians’ confusion over the drug have made them hesitant to prescribe it, The New York Times reported March 6.
Read the full post on Becker's Hospital Review - Healthcare News
